Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
Part of paid clinical trials in Albert Lea, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT06325046
- Status
- Recruiting
Conditions
- Localized Prostate Adenocarcinoma
- Stage I Prostate Cancer AJCC v8
- Stage II Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Computed Tomography — PROCEDUREUndergo CT
- Cone-Beam Computed Tomography — PROCEDUREUndergo CBCT
- Image-Guided Adaptive Radiation Therapy — RADIATIONUndergo near margin-less ART
- Magnetic Resonance Imaging — PROCEDUREUndergo MRI
- Stereotactic Ablative Radiotherapy — PROCEDUREUndergo standard SABR
- Survey Administration — OTHERAncillary studies
Study Details
This clinical trial evaluates changes in quality of life after two treatments with near margin-less adaptive radiation therapy (ART) compared to five treatments with standard stereotactic ablative body radiotherapy (SABR) in patients with prostate cancer that has not spread to other parts of the body (localized). ART is a type of radiation therapy that uses information gathered during the treatment cycle to inform, guide, and alter future radiation treatments with respect to location and dose. It may be able to deliver radiation to the site of disease over a shorter time and with smaller margins (less treatment delivered to nearby healthy tissues). SABR is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Shorter duration near margin-less ART may be just as effective at treating patients with localized prostate cancer but have less quality of life side effects than standard SABR.
Key Dates
- Start date
- Aug 15, 2024
- Status verified
- Mar 2026
- Primary completion
- Aug 30, 2026
- Completion
- Aug 30, 2031
Study Design
- Enrollment
- 144 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm I (near margin-less ART)Patients undergo near margin-less ART for 2 treatments at least 3 days apart in the absence of disease progression or unacceptable toxicity. Patients also undergo CBCT and may undergo CT and/or MRI on study.
- Active Comparator: Arm II (standard SABR)Patients undergo standard SABR for 5 treatments at least 2 days apart in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI on study.
Primary Outcome Measure
Treatment-related, patient-reported early quality of life (QOL) changes [ Time Frame: Baseline; up to 3 months ]
Central Contacts
- Clinical Trials Referral Office855-776-0015
Locations (5)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic Health System in Albert Lea | Albert Lea | Minnesota | 56007 | John Yeakel, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Health System-Mankato | Mankato | Minnesota | 56001 | Lydia W. Ng, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Mark R. Waddle, M.D. (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Health System-Eau Claire | Eau Claire | Wisconsin | 54701 | Now Bahar Alam, MD (PRINCIPAL_INVESTIGATOR) |
| Mayo Clinic Health System-Franciscan Healthcare | La Crosse | Wisconsin | 54601 | Abigail L. Stockham, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Albert Lea, MN
Related Studies
- Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE TrialPHASE3 · Recruiting · NRG Oncology · Phoenix, Arizona
- MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Low to Intermediate Grade Prostate CancerRecruiting · Mayo Clinic · Rochester, Minnesota
- Vitamin D for Prostate Endocrine TherapyPHASE3 · Recruiting · University of Rochester · Newark, Delaware
- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate CancerPHASE3 · Recruiting · NRG Oncology · Birmingham, Alabama